No correlation was found between the extent or the position of the deletion and the clinical phenotype, whereas strong correlation exists with the status of the reading frame in the mRNA resulting from deletion.3
Several studies have reported that the great majority of cases affected by Duchenne or Becker muscular dystrophy are the result of deletions in the dystrophin gene, mapping in Xp21. Most deletions occur in two regions, one of which was first identified by pERT probes' and the second by the probe P20. 2 No correlation was found between the extent or the position of the deletion and the clinical phenotype, whereas strong correlation exists with the status of the reading frame in the mRNA resulting from deletion. 3 Immunohistochemistry and immunoblotting showed that 85% of DMD/BMD patients with unequivocal labelling on blots had a protein of abnormal size, while 15% had a dystrophin of normal size but of reduced amount,45 suggesting the possibility of regulatory mutations. Studies on the regulation and expression of the dystrophin gene led to identification of different promoters, one of which is specific for muscle.69
The present study deals with the molecular analysis of dystrophin gene mutations in a series of 115 unrelated Italian DMD/BMD patients, with special reference to deletions in the muscle promoter region or in coding sequences or both. Samples were incubated for one minute at 95°C, followed by one minute at 65'C for annealing, and one minute at 72'C for elongation. The amplification cycle was repeated 35 times and the reaction ended with five minutes of elongation at 72'C. Amplification products were run on 15% agarose or 5% acrylamide gel and subsequently stained by ethidium bromide solution.
Materials and methods
Muscle promoters from controls and from patients affected with BMD, amplified by PCR and purified on low melt agarose, were individually cloned in pUCl9 using the restriction sites added to the primer sequence.
Plasmid DNA was directly sequenced on both strands using Sequenase 2-0 (USB) with two nested primers (Fwd CACTGTGCTA-TTCTGGTTTGG; Rev CTTTGTACTT-ACAACAGTCCTC). (fig 4) .
Results
None of these 38 patients showed deletions in the segment that includes the muscle promoter. As expected, no promoter deletions were found among patients showing exonic deletions or showing a dystrophin altered in size.
The muscle promoter regions of the three BMD patients showing reduced levels of normal dystrophin (less than 50% of normal) were cloned in pUC19 and sequenced. Four independent clones were analysed for each patient and for two unrelated healthy male controls. The comparison of sequences showed minor variations in one control and in one BMD patient (deletion of a T in a series of seven in one, and in a series of eight in the other), but no significant differences were present (data not shown).
Discussion
The absence of gross mutations in the region of the muscle promoter is not surprising, because of the small size of the sequence involved and the presumed selective pressure for the conservation of consensus sequences. A deletion of the promoter region has only been described once so far.9 The rarity of this kind of mutation is confirmed by the present study, where no promoter deletions were found in a series of 115 unrelated patients.
None of the three BMD cases with reduced dystrophin of normal size showed mutations in the sequence including the muscle promoter, but the reduction of dystrophin molecules might be the result of point mutations in the coding sequence. Such mutations could make the protein more prone to rapid degradation. Alternatively, the observed reduction of dystrophin could be explained by mutation in still undefined additional regulation sites.
The large majority (86%) of 5' deletion breakpoints found in the present study map between the exons identified by cDNA probes 7 
